Updated Results from an Open-Label, Multicenter, Expanded Treatment Protocol (ETP) Phase (Ph) 3b Study of Ruxolitinib (RUX) in Patients (Pts) with Polycythemia Vera (PV) Who Were Hydroxyurea (HU) Resistant or Intolerant and for Whom No Alternative Treatment (Tx) Was Available

Autor: Foltz, Lynda, Pica, Gian-Matteo ^*, Zerazhi, Hacene ^*, Van Droogenbroeck, Jan ^*, Visanica, Sorin ^*, Báez de la Fuente, Enrique ^*, Leber, Brian, de Almeida, Antonio Medina ^*, Ranta, Dana ^*, Cartes, Mauricio Reyes ^*, Kiladjian, Jean-Jacques, Chrit, Linda ^*, Yin, Zhaoyu ^*, Morando, Juliane ^*, Devos, Timothy

Publikováno v: In Blood 29 November 2018 132 Supplement 1:1774-1774

Can the Autologous Transplant of Hematopoyetic Progenitors be Considered an Effective Alternative to Increase Global Survival in High-Grade Non-Hodgkin Lymphomas?

Autor: Ramirez Lopez, Alba Nydia, Baez De La Fuente, Enrique ^*, De Leon Cantu, Rosa Elva ^*, Cruz Contreras, Diego ^*, Carrizalez Villarreal, Jose Alfredo ^*, Cedillo De La Cerda, Jose Luis ^*, Saldaña Vazquez, Roxana ^*, Sorkee Davila, Helga Patricia ^*, Rosas Rodríguez, Axel Eduardo ^*, Baltazar Arellano, Severiano ^*, Hernandez Valdes, Roberto ^*, Lafarga Amao, Bernardo ^*, Lozano, Rosa ^*, Terrazas, Andrea ^*

Publikováno v: In Blood 8 December 2017 130 Supplement 1:5520-5520

[Hematologic and molecular response with dasatinib as second-line treatment in chronic myeloid leukemia (CML) with treatment failure].

Autor: Santos-Macías JE; Departamento de Hematología, UMAE No 25, Monterrey, N.L., México., Baez de la Fuente E; Departamento de Hematología, UMAE No 25, Monterrey, N.L., México., Salas-Delgado A; Departamento de Hematología, UMAE No 25, Monterrey, N.L., México.

Publikováno v: Gaceta medica de Mexico [Gac Med Mex] 2016 May-Jun; Vol. 152 (3), pp. 334-8.